| 494.46 8.13 (1.67%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 578.74  |
1-year : | 675.97 |
| Resists | First : | 495.5 |
Second : | 578.74 |
| Pivot price | 466.9 |
|||
| Supports | First : | 428.46 |
Second : | 387.03 |
| MAs | MA(5) : | 475.8 |
MA(20) : | 458.72 |
| MA(100) : | 397.84 |
MA(250) : | 432.18  |
|
| MACD | MACD : | 18.7 |
Signal : | 18.2 |
| %K %D | K(14,3) : | 85.8 |
D(3) : | 82.5 |
| RSI | RSI(14): 70.2 |
|||
| 52-week | High : | 532.59 | Low : | 327.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARGX ] has closed above the upper band by 5.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 2.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 496.14 - 498.15 | 498.15 - 500.06 |
| Low: | 469.01 - 471.19 | 471.19 - 473.26 |
| Close: | 490.89 - 494.39 | 494.39 - 497.72 |
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Fri, 26 Jul 2024
argenx SE returns to growth driven by Vyvgart, H.C. Wainwright raises shares PT - Investing.com
Fri, 26 Jul 2024
argenx (NASDAQ:ARGX) Shares Gap Down to $486.33 - MarketBeat
Fri, 26 Jul 2024
argenx shares target lifted on revenue growth prospects - Investing.com
Fri, 26 Jul 2024
argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Thu, 25 Jul 2024
Argenx Is Expanding Its Autoimmune Portfolio With New Vyvgart Approvals and Pipeline Candidates - Morningstar
Thu, 25 Jul 2024
argenx SE (ARGX) Q2 2024 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 57.9 (%) |
| Shares Short | 1,550 (K) |
| Shares Short P.Month | 1,290 (K) |
| EPS | -5.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 69.22 |
| Profit Margin | -22.6 % |
| Operating Margin | -22.3 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 79.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 24.24 |
| EBITDA (p.s.) | -5.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -86.75 |
| PEG Ratio | -2.5 |
| Price to Book value | 7.14 |
| Price to Sales | 20.39 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|